.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,750,023

« Back to Dashboard

Details for Patent: 7,750,023

Title:Quinuclidine derivatives and medicinal compositions containing the same
Abstract: The invention provides 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo- [2.2.2]octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, in association with .beta..sub.2 agonist.
Inventor(s): Fernandez Forner; Maria Dolors (Barcelona, ES), Prat Quinones; Maria (Barcelona, ES), Buil Albero; Maria Antonia (Barcelona, ES)
Assignee: Almirall, S.A. (N/A)
Filing Date:Mar 07, 2008
Application Number:12/074,929
Claims:1. A pharmaceutical composition comprising: (i) 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo- [2.2.2]octane, wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid; and (ii) a .beta..sub.2 agonist.

2. The composition of claim 1 comprising 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo- [2.2.2]octane bromide.

3. The composition of claim 1 in admixture with a pharmaceutically acceptable carrier or diluent.

4. The composition of claim 3 comprising 3(S)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2]octane, wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

5. The composition of claim 4 comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2]octane, wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

6. The composition of claim 1 wherein the pharmaceutical composition is suitable for inhalation.

7. The pharmaceutical composition according to claim 1 further comprising a steroid or phosphodiesterase IV inhibitor.

8. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective amount of: (i) 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo- [2.2.2]octane, wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid; and (ii) a .beta..sub.2 agonist.

9. The method according to claim 8, wherein the anion X.sup.- is Br.sup.-.

10. The method of claim 8 comprising administering an effective amount of 3(S)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicy- clo[2.2.2]octane, wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

11. The method of claim 10 comprising administering an effective amount of 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniab- icyclo[2.2.2]octane, wherein an anion X.sup.- is associated with the positive charge of the nitrogen atom and wherein X.sup.- is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

12. The method of claim 8 wherein administration is by inhalation.

13. The method of claim 8 comprising administering an effective amount of a steroid or phosphodiesterase IV inhibitor.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc